Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma

May 20, 2019

Management of Multiple Myeloma
On one hand the availability of various classes of agents has significantly improved patient outcomes but on the other presents challenges to clinicians in terms of selecting optimal frontline therapy for MM, determining the nature and duration of maintenance, and selecting the ideal sequence of therapy at relapse. The key to maximizing treatment and supportive care outcomes for patients with MM lies in careful choice of individualized treatment regimens along with early recognition and management of treatment or MM-associated adverse events. Many factors need to be considered when determining the optimal MM treatment: age, prognostic factors, comorbidities, toxicity profiles, response to prior therapy, previous relapses and patient preferences. Moreover, the variety of available supportive care measures targeting adverse symptoms related to MM or MM therapy have to be tailored to a specific patient. Clinicians need to be aware of the range of factors involved in managing the treatment and supportive care of patients with MM.  It is important for clinicians to discuss practical patient examples and the rationale for the various treatment choices based on expert experience and recent data from trials to aid the decision-making process for clinicians treating patients with myeloma.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Evaluate the benefits and risks associated with therapies and use evidence-based data and patient characteristics to select an optimal management strategy for patients with newly diagnosed MM.
  • Analyze efficacy and tolerability of therapies for the management of relapsed MM and effectively counsel patients.
  • Use evidence-based data to manage bone disease and other complications in patients with MM.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Bayer U.S. LLC
  • Celgene Corporation
  • Clovis Oncology
  • Eisai
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • Lilly
  • Novartis
  • Taiho Oncology

This activity is supported by an independent educational grant from TESARO.

This activity is supported by an independent medical education grant from Bristol-Myers Squibb.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
04/03/2019
Course expires: 
07/14/2019
Event starts: 
05/20/2019 - 2:30pm
Event ends: 
05/20/2019 - 3:30pm
Cost:
$0.00
Parent activity set: 

Natalie S. Callander, MD
University of Wisconsin Carbone Cancer Center

Michelle L. Lakner, MSN
University of Wisconsin Carbone Cancer Center

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Full disclosure of faculty relationships will be made prior to the activity.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-19-028-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Accreditation Period

Course opens: 
04/03/2019
Course expires: 
07/14/2019

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

This webinar will be presented live one time only on Monday, May 20, 2019, from 2:30 - 3:30 PM Eastern Daylight Time (EDT) (UTC -4).  To adjust for other time zones, click here.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing